Digital biomarkers are measurable data signals collected from digital devices or software that indicate a person’s health state, behaviour or physiological function. They may come from smartphones, wearables or apps, and are used as indicators rather than direct diagnostic measurements.
What Digital Biomarkers Are Used For
Digital biomarkers turn device and software activity into measurable signals that can support screening, monitoring, stratification, and follow-up. In practice, they sit between raw telemetry and clinical interpretation, so their value depends on whether the measurement is repeatable, clinically meaningful, and collected in a way that preserves context.
Because these signals may come from consumer devices as well as regulated health tools, the same behaviour can mean very different things depending on sampling quality, patient population, environment, and how the signal is interpreted. That makes digital biomarkers useful, but also easy to overstate if the underlying data path is noisy or incomplete.
How Digital Biomarkers Are Collected and Interpreted
Digital biomarkers are usually assembled from sensors, usage patterns, timestamps, location-adjacent data, motion data, speech, typing patterns, or other software-generated events. The measurement layer matters as much as the analysis layer, because calibration drift, missing samples, device heterogeneity, and background noise can all change the signal without any real change in health state.
Interpretation also depends on the intended use. A signal that works well for trend monitoring may not be reliable enough for diagnosis, and a biomarker that is useful in one app or cohort may not transfer cleanly to another. That is why digital biomarkers are generally best treated as decision-support inputs, not standalone proof of condition.
Why Data Quality, Context, and Validation Matter
The main challenge with digital biomarkers is not collecting data, it is proving that the data means what people think it means. A strong biomarker needs defined collection conditions, consistent device behaviour, and validation against an outcome that is independently meaningful. Without that, the signal can become a proxy for device usage habits rather than physiology or behaviour.
Context is equally important. Sleep, mobility, medication timing, work patterns, and device sharing can all distort the interpretation of a signal. Good programmes therefore separate measurement fidelity from clinical significance and avoid treating every observed pattern as a true biomarker.
Where Digital Biomarkers Create Security and Privacy Concerns
Digital biomarkers can expose highly sensitive personal and health-related information because the same data that supports analysis can also reveal routines, movement, communication patterns, or other intimate behaviour. If the data is intercepted, repurposed, or linked to the wrong person, the harm extends beyond confidentiality into trust, consent, and potentially clinical misuse.
Failure mechanism: weak collection controls, poor identity binding, insecure APIs, or over-retention can allow biomarker data to be altered, reidentified, or accessed outside its intended use. In regulated or health-adjacent environments, that can undermine study integrity, patient trust, and the evidential value of the signal itself.
Impact: compromised digital biomarker pipelines can produce false clinical inferences, expose protected health information, and contaminate downstream models or decisions. Strong governance for data minimisation, access control, and validation is therefore part of the biomarker problem, not an afterthought.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and NIST CSF 2.0 set the technical controls, while GDPR defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| GDPR | Art. 5 — Principles Relating to Processing of Personal Data | Digital biomarkers may be personal and health data requiring lawful, minimised processing. |
| Art. 9 — Processing of Special Categories of Personal Data | Health-state biomarker data can fall within special-category personal data protections. | |
| Art. 25 — Data Protection by Design and by Default | Biomarker pipelines should embed privacy and purpose limitation into collection design. | |
| Recommendation — Minimise collection and limit use to the stated biomarker purpose. Apply special-category safeguards before collecting or analysing health-linked signals. Build privacy controls into the biomarker workflow from the start. | ||
| NIST SP 800-53 Rev 5 | AU-2 — Audit Events | Biomarker platforms need logging to reconstruct data access and signal handling. |
| IA-2 — Identification and Authentication (Organizational Users) | Clinical and research users must be authenticated before accessing biomarker data. | |
| AC-6 — Least Privilege | Access to sensitive biomarker data should be restricted to the minimum necessary users. | |
| Recommendation — Log biomarker access, changes, and administrative actions. Require strong user authentication for biomarker systems. Restrict biomarker access to the minimum necessary roles. | ||
| NIST CSF 2.0 | PR.DS-01 — Data-at-rest is protected | Biomarker datasets need confidentiality protections while stored and retained. |
| PR.AA-05 — Privileges and access are managed | Access governance is central to handling sensitive biomarker information responsibly. | |
| Recommendation — Protect stored biomarker data with strong encryption and access controls. Manage and review access to biomarker datasets and tools. | ||
Practitioner Guidance
Why practitioners should care: Digital biomarkers only become operationally useful when the collection method, context, and interpretation are controlled tightly enough to support the intended decision. If those boundaries are loose, the result may look scientific while remaining too fragile for real use.
What to watch for: Be cautious when a signal is inferred from a single device type, an unvalidated app workflow, or data that can be changed by user behaviour unrelated to health. That is often where false confidence starts.
Practitioner takeaway: Treat digital biomarkers as governed measurement systems, not just analytics outputs; the reliability of the measurement path determines whether the signal is clinically or operationally useful.
Related resources from NHI Mgmt Group
- What is the difference between identity forensics and standard digital forensics?
- How should organisations govern access across many APIs in a digital transformation programme?
- Why does digital transformation make identity governance harder?
- What do security teams get wrong about customer identity in digital commerce?
Deepen Your Knowledge
Free weekly newsletter
Subscribe to the NHI & AI Identity Journal
The latest on NHI and Agentic AI security – articles, research, breaches, news and events every week.
Bonus 33% off our NHI Course when you subscribe.
Reviewed and updated by the NHIMG editorial team on November 9, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org